Jazz Pharmaceuticals plc (JAZZ) Revenue History
Annual and quarterly revenue from 2014 to 2025
Compound Annual Growth Rate (CAGR)
Loading revenue history...
JAZZ Revenue Growth
Revenue Breakdown (FY 2025)
JAZZ's revenue distribution by segment and geography for fiscal year 2025
By Product/Segment
By Geography
JAZZ Revenue Analysis (2014–2025)
As of May 8, 2026, Jazz Pharmaceuticals plc (JAZZ) generated trailing twelve-month (TTM) revenue of $4.44 billion, reflecting strong growth of +19.1% year-over-year. The most recent quarter (Q1 2026) recorded $1.07 billion in revenue, down 10.8% sequentially.
Looking at the longer-term picture, JAZZ's 5-year compound annual growth rate (CAGR) stands at +12.5%, indicating consistent double-digit revenue growth. The company achieved its highest annual revenue of $4.27 billion in 2025, representing a new all-time high.
Revenue diversification analysis shows JAZZ's business is primarily driven by Xywav (40%), Epidiolex/Epidyolex (25%), and Rylaze/Enrylaze (10%).
When compared to Healthcare sector peers including SUPN (+16.3% YoY), PCRX (+4.6% YoY), and INVA (+13.6% YoY), JAZZ has outperformed the peer group in terms of revenue growth. Compare JAZZ vs SUPN →
JAZZ Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| JAZZCurrent | $4.4B | +19.1% | +12.5% | 5.3% | |
 SUPN | $719M | +16.3% | +6.7% | -5.1% | |
 PCRX | $726M | +4.6% | +11.1% | 4.6% | |
 INVA | $425M | +13.6% | +4.8% | 38.5% | |
 AVNS | $701M | +3.9% | -0.4% | -8.8% | |
 PRGO | $4.3B | -3.6% | +0.8% | 8.1% |
JAZZ Historical Revenue Data (2014–2025)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $4.27B | +4.9% | $3.76B | 88.2% | $224.4M | 5.3% |
| 2024 | $4.07B | +6.1% | $3.62B | 89.0% | $716.6M | 17.6% |
| 2023 | $3.83B | +4.8% | $3.40B | 88.6% | $578.6M | 15.1% |
| 2022 | $3.66B | +18.3% | $3.12B | 85.2% | $-65,528,000 | -1.8% |
| 2021 | $3.09B | +30.9% | $2.65B | 85.8% | $170.3M | 5.5% |
| 2020 | $2.36B | +9.3% | $2.21B | 93.7% | $378.1M | 16.0% |
| 2019 | $2.16B | +14.3% | $2.03B | 94.1% | $532.4M | 24.6% |
| 2018 | $1.89B | +16.8% | $1.77B | 93.6% | $614.8M | 32.5% |
| 2017 | $1.62B | +8.8% | $1.51B | 93.2% | $528.8M | 32.7% |
| 2016 | $1.49B | +12.3% | $1.38B | 92.9% | $591.7M | 39.8% |
Full JAZZ Stock Analysis
Analyst consensus, bull case, AI-generated risk factors, and peer comparison — all in one place.
See JAZZ's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs JAZZ Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare JAZZ vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonJAZZ — Frequently Asked Questions
Quick answers to the most common questions about buying JAZZ stock.
Is JAZZ's revenue growth accelerating or slowing?
JAZZ revenue is accelerating at +19.1% year-over-year, exceeding the 5-year CAGR of +12.5%. TTM revenue reached $4.4B. Growth momentum has increased versus prior periods.
What is JAZZ's long-term revenue growth rate?
Jazz Pharmaceuticals plc's 5-year revenue CAGR of +12.5% reflects the sustained expansion pattern. Current YoY growth of +19.1% is above this long-term average.
How is JAZZ's revenue distributed by segment?
JAZZ reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2014-2025 are available for download. Segment mix reveals concentration and diversification trends.